Expression of two isoforms of Lep d 2, the major allergen of Lepidoglyphus destructor, in both prokaryotic and eukaryotic systems

Clin Exp Allergy. 1998 Aug;28(8):984-91. doi: 10.1046/j.1365-2222.1998.00375.x.

Abstract

Background: The dust mite Lepidoglyphus destructor is a major cause of allergic diseases among farmers. We have previously cloned and sequenced two isoforms of the major allergen Lep d 2 (formerly designated Lep d 1) and found significant homology to group 2 allergens of the house dust mite species Dermatophagoides. We now report on the production and characterization of recombinant Lep d 2.

Objective: We have expressed both isoforms in two different expression systems; a eukaryotic system, baculovirus in insect cells and a prokaryotic system, E. coli. We have compared the two systems in regard to production yields and immunoreactivity of the recombinant allergens.

Methods: The complete cDNA including the natural leader sequence was cloned into the pBlueBacIII transfer vector, and the rLep d 2 was produced as a secreted protein in baculovirus. For the expression in E. coli, the cDNA was cloned into the pET vector, and the rLep d 2 was produced with six C-terminal histidine residues. The purified recombinant allergens were tested for immunoreactivity with 10 sera from subjects allergic to Lepidoglyphus destructor and were compared with native Lep d 2 using inhibition immunoblotting. The ability of the recombinant allergens to release histamine from basophils was evaluated using a histamine release assay.

Results: Both expression systems produced immunoreactive recombinant allergens. They inhibited the binding of human sera to native Lep d 2 confirming their retained IgE binding properties. The yield of pure recombinant protein from the prokaryotic system was approximately 1 mg/L compared to the eukaryotic system which produced up to 4 mg/L in an adherent cell culture system.

Conclusions: We have produced recombinant Lep d 2 in prokaryotic and eukaryotic expression systems which are comparable to the native allergen. Recombinant Lep d 2 might now be included in more extensive clinical studies to confirm its usefulness in the in vitro and the in vivo diagnosis of Lepidoglyphus destructor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Allergens / biosynthesis*
  • Allergens / genetics
  • Allergens / immunology
  • Animals
  • Asthma / immunology
  • Baculoviridae / genetics
  • Basophils / immunology
  • Cloning, Molecular / methods*
  • Conjunctivitis, Allergic / immunology
  • DNA Primers / chemistry
  • Electrophoresis, Polyacrylamide Gel
  • Escherichia coli / genetics
  • Gene Expression
  • Genetic Vectors
  • Histamine Release / immunology
  • Humans
  • Immunoblotting
  • Insecta
  • Mites*
  • Protein Biosynthesis*
  • Proteins / genetics
  • Proteins / immunology
  • Recombinant Proteins / biosynthesis
  • Recombinant Proteins / genetics
  • Recombinant Proteins / immunology
  • Rhinitis, Allergic, Perennial / immunology

Substances

  • Allergens
  • DNA Primers
  • Lep d I allergen
  • Proteins
  • Recombinant Proteins